153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
Knop
Stefan
S
Dept. of Hematology and Oncology, Tuebingen University Hospital, Tuebingen, German. stefan.knop@med.uni-tuebingen.de
Dohmen
Bernhard M
BM
Kanz
Lothar
L
Bares
Roland
R
Einsele
Hermann
H
D017809:Fatal Outcome; D006085:Graft Survival; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010014:Osteolysis / Q000209:etiology / Q000532:radiotherapy; D036102:Peripheral Blood Stem Cell Transplantation; D011868:Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016879:Salvage Therapy; D012493:Samarium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C018940:(ethylenedinitrilo)-tetramethylenephosphonic acid; D012493:Samarium; C061972:samarium Sm-153 lexidronam; D008558:Melphalan